We recently published an article titled, Jim Cramer’s Latest Lightning Round: 12 Stocks to Watch. In this article, we are ...

We recently published a list of 10 Best Medical Stocks to Buy Now. In this article, we are going to take a look at where ...

IQ EQ FUND MANAGEMENT IRELAND Ltd lessened its position in shares of AbbVie Inc. (NYSE:ABBV – Free Report) by 3.0% during the ...

Vyalev is the first subcutaneous 24-hour continuous infusion of levodopa-based therapy for advanced Parkinson’s disease.

On Thursday, AbbVie Inc (ABBV) stock saw a decline, ending the day at $188.57 which represents a decrease of $-1.89 or -0.99% from the prior close of $190.46. The stock opened at $190.54 and touched a ...

AbbVie Inc. (NYSE: ABBV) is rewarding its shareholders once again with a quarterly dividend of $1.55, payable on Tuesday Oct.

On Friday, AbbVie Inc (ABBV) stock saw a decline, ending the day at $194.19 which represents a decrease of $-0.16 or -0.08% from the prior close of $194.35. The stock opened at $195 and touched a low ...

AbbVie Inc. (NYSE:ABBV – Get Free Report)’s share price was up 0.1% during mid-day trading on Friday after Truist Financial ...

AbbVie Inc., which split from Abbott Laboratories remains more than a decade ago, is doing "very, very well," Jim Cramer says.

(RTTNews) - AbbVie Inc. (ABBV) Thursday said that the U.S. Food and Drug Administration (FDA) has approved Vyalev for the treatment of motor fluctuations in adults with advanced Parkinson's disease ...

The U.S. FDA has approved the first 24-hour continuous subcutaneous infusion for adults with advanced Parkinson’s disease.

Shares of AbbVie Inc. ABBV shed 1.15% to $191.86 Tuesday, on what proved to be an all-around poor trading session for the stock market, with the S&P 500 Index SPX falling 0.76% to 5,815.26 and Dow ...